Trial reportFrontiers in medicine2025
Application of erector spinae plane block and thoracic paravertebral block in thoracoscopic lobectomy.
Trial report in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Compare the effects of erector spinae plane block (ESPB) and thoracic paravertebral block (TPVB) in perioperative pain management for thoracoscopic lobectomy. Methods: From September 2024 to June 2025, 99 patients with pulmonary space-occupying lesions scheduled for thoracoscopic lobectomy were enrolled and randomly assigned to three groups (33 each): the control group, the ESPB group, and the TPVB group. Baseline data covered gender, age, body mass index, tumor-node-metastasis stage, American Society of Anesthesiologists grade, surgery duration, and resection site. Primary outcomes were resting and coughing visual analogue scale (VAS) scores in the postanesthesia care unit at 2, 4, 8, 16, and 24 h postoperatively. Secondary outcomes included heart rate (HR), mean arterial pressure (MAP), adverse reactions, opioid consumption, time to first ambulation, hospital stay, and drainage tube duration. Results: Baseline data were comparable. ESPB and TPVB groups had lower VAS scores and area under curve (AUC) than the control group ( Conclusion: Both TPVB and ESPB can effectively relieve postoperative pain, reduce stress responses, and shorten recovery time after thoracoscopic lobectomy. TPVB offers better early analgesia and hemodynamic stability. Clinical trial registration: www.chictr.org.cn, Identifier, ChiCTR2100054074, 2021/12/08.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.